Rare target detection of lung cancer, so that every "rare" is "seen"

At the 5th China International Import Expo (hereinafter referred to as the "Expo"), Roche Diagnostics and Roche Pharmaceutical, together with seven leading domestic genetic testing medical technology partners, signed a contract to establish the "Lung Cancer Rare Target Ecological Alliance"
.
The alliance will fully integrate the advantages of diagnostics and pharmaceuticals, work together to build an innovative lung cancer diagnosis and treatment ecosystem in China, provide innovative pathological diagnosis products and services for rare targets of lung cancer, empower the improvement of personalized and precise diagnosis and treatment of lung cancer, and help realize the vision
of "Healthy China 2030".

"Healing" sees hope for survival: the "chronic disease" of lung cancer is possible

The annual number of new cases and deaths of lung cancer in China is as high as 815,000 and 713,000 respectively^[1], ranking first
among all malignant tumors.
Among lung cancers, non-small cell lung cancer is the most common type of lung cancer, accounting for 85-90% of all lung cancers, of which about 3-7% of patients have ALK gene fusion
.
Professor Zhou Caicun of Shanghai Pulmonary Hospital affiliated to Tongji University introduced: "The average age of ALK-positive non-small cell lung cancer patients is relatively low, and it is accompanied by high risk of recurrence, high incidence of brain metastasis, and poor prognosis
.
Continued advances in precision medicine have allowed clinicians to gain valuable life time
for ALK-positive non-small cell lung cancer patients.
^[2]”

In order to systematically analyze the current quality of life, treatment status and real needs of ALK-positive non-small cell lung cancer patients in China (hereinafter referred to as ALK-positive NSCLC), Professor Zhou Caicun, chairman of the Lung Cancer Special Committee of the Chinese Society of Clinical Oncology (CSCO), led the launch of the "2022 Non-small Cell Lung Cancer ALK-positive Patients Survival Status Survey White Paper" (hereinafter referred to as the "White Paper"), based on the preliminary exploration in 2021.
In 2022, the project expanded the number of researchers to 3085 patients, which is also the largest sample size of ALK-positive NSCLC patients in the world, and comprehensively evaluated the survival status
of ALK-positive NSCLC patients in terms of treatment journey, quality of life, drug accessibility, patient education and information acquisition.

Professor Zhou Caicun, Shanghai Pulmonary Hospital affiliated to Tongji University

With the continuous emergence of targeted therapy drugs, the prognosis of ALK-positive NSCLC patients has been significantly improved, and lung cancer may be "chronic disease"
.
Professor Zhou Caicun introduced: "According to the preliminary analysis of the survey results, the overall satisfaction of ALK-positive NSCLC patients in first-line treatment is high, and the second-generation ALK inhibitor (aletinib) ranks first in the satisfaction evaluation
.
When we make drug selection, we should fully consider the patient's long-term survival background, and it is our goal
to bring a better life to patients.
”

Identify "diamond" mutations: "see" every "rare"

Precision medicine, detection first
.
Determining the molecular typing of lung cancer through pathological diagnosis is a prerequisite
for NSCLC targeted therapy.
Therefore, it is of great clinical significance
to select accurate, rapid and reliable detection methods to accurately identify the target population suitable for targeted drugs, especially the NSCLC population with rare "diamond" mutations.

In order to ensure the accuracy and efficiency of ALK detection results, help clinical applications of targeted drugs more targeted, and promote the standardization of ALK detection
.
In the current clinical application in China, the detection methods of ALK at the diagnostic level of NSCLC are mainly
immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), instant real-time quantitative polymerase chain reaction (RT-PCR) and next-generation sequencing (NGS).
Compared with ALK detection based on other methodologies, Roche diagnostic VENTANA ALK (D5F3) IHC test has obvious advantages
such as economy, rapidity, easy to carry out, easy to interpret, and sufficient clinical trial verification.
THE CHINA EXPERT CONSENSUS ON CLINICAL PRACTICE OF ALK DETECTION FOR NON-SMALL CELL LUNG CANCER STRONGLY RECOMMENDS THE PRIORITY USE OF VENTANA ALK (D5F3) IHC FOR ALK DETECTION
.

RESEARCH AND CLINICAL PRACTICE HAVE PROVED THAT VENTANA ALK (D5F3) IBC DETECTION CAN EFFECTIVELY HELP THE ACCURATE IDENTIFICATION OF ALK-POSITIVE NSCLC PATIENTS, MAXIMIZE THE NUMBER OF "DIAMOND" MUTATION PATIENTS WHO MAY IMPROVE OUTCOMES, SO THAT EVERY "RARE" MUTATION NSCLC PATIENT CAN BE "SEEN" AND BENEFIT
FROM TARGETED THERAPY.

Bringing together the advantages of all parties: creating an innovative Chinese lung cancer ecosystem

In order to comprehensively improve the diagnosis and treatment level of rare targets of NSCLC in various regions and promote homogeneous diagnosis and treatment in all levels of regions, at this Expo, Roche Diagnostics and Roche Pharmaceutical, together with seven domestic genetic testing medical technology partners, namely Genetron Gene Technology, BGI, Jinyu Medical, Giinga, Burnstone Medicine, Zhiben Medical Technology, and Zhenhe Technology, jointly established the "Lung Cancer Rare Target Ecological Alliance", and all parties will strengthen cooperation in the fields of improving the standardized diagnosis and treatment of rare targets of lung cancer and patient education.
It aims to explore innovative medical solutions and jointly contribute to the construction of a local medical innovation ecosystem to benefit Chinese patients
.

Signing ceremony of the Ecological Alliance for Rare Targets of Lung Cancer

Ms.
Bian Xin, General Manager of Roche Pharmaceutical, said: "This year is the fifth year that Roche has participated in CIIE, and it is also a harvest year
for us to achieve several important milestones in the field of lung cancer.
In the future, Roche will continue to uphold the concept of 'putting patients first', work together with partners from all walks of life, and help the process of chronic lung cancer in an open and win-win attitude, so that more Chinese lung cancer patients can fully and effectively benefit, and realize the grand vision
of 'Healthy China 2030' as soon as possible.
" ”

Mr.
Yao Guoliang, General Manager of Roche Diagnostics China, said: "Roche has always been committed to integrating the advantages of pharmaceutical and diagnostics with practical actions, and continues to fulfill its long-term commitment
to the Chinese market.
It is hoped that through the establishment of this alliance, innovation and resource complementarity will improve the accessibility of high-quality diagnostic solutions in the Chinese market, jointly build an innovative personalized precision diagnosis and treatment ecosystem for lung cancer in China, improve the level of precision diagnosis and treatment of lung cancer in China, and benefit more Chinese patients
.
”

Mr.
Yao Guoliang, General Manager of Roche Diagnostics China

References:

[1]

[2] JIANG Tao, ZHOU Caicun.
Mechanism and therapeutic measures of crizotinib resistance in patients with ALK-positive non-small cell lung cancer.
Chinese Journal of Lung Cancer.
2015.

This platform is designed to deliver more medical information
to healthcare professionals.
The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
.
The content published by this platform does not mean that it agrees with its description and views
.
If copyright issues are involved, please contact us and we will deal with
it as soon as possible.